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Systemic  capillary  leak  syndrome  (SCLS)  is  a  condition  that's  caused  by  the  shift  of  fluid  and  protein  from  the 
intravascular  space  to  the  interstitial  space  as  a  result  of  repetitive  episodes  of  capillary  hyperpermeability.  The 
pathogenesis  of  SCLS  is  still  unclear,  but  there's  recently  been  a  report  showing  this  syndrome  in  association  with 
monoclonal  gammopathy.  This  syndrome  can  be  a  fatal  disease  because  cardiovascular  collapse  can  occur  in  the 
initial  capillary  leak  phase.  Although  theophylline,  diuretics,  terbutaline,  steroids,  calcium  antagonist,  Ginkgo  biloba 
extracts  and  plasmapheresis  have  been  suggested  as  medication,  none  of  them  have  been  proven  to  be  effective. 
Considering  that  this  disease  is  self-limiting,  conservative  treatment  in  the  acute  phase  is  believed  to  be  very  important. 
Because  hypoalbuminemia  is  very  a  common  manifestation  of  SCLS,  Pentastarch,  which  has  a  higher  molecular 
weight  than  albumin,  could  be  efficient  to  prevent  cardiovascular  collapse.  We  used  10%  Pentastarch  during  the  acute 
SCLS  attacks  of  2  patients  and  the  patients  both  showed  a  dramatic  response.  Pentastarch  may  be  helpful  to  treat 
SCLS  in  its  initial  capillary  leak  phase  by  the  elevating  blood  pressure,  and  this  might  contribute  to  somewhat 
decreasing  the  acute  mortality  of  SCLS.
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INTRODUCTION
Systemic  capillary  leak  syndrome  (SCLS)  is  a  disorder 
characterized  by  unexplained  episodic  capillary  hyperpermeability, 
which  causes  the  shift  of  fluid  and  protein  from  the  intravascular 
space  to  the  interstitial  space
1).  It  is  a  rare,  but  often  fatal 
disease
1).  Since  no  effective  treatment  has  so  far  been  found, 
this  disease  could  lead  to  death  if  the  blood  pressure  is  not 
increased  during  the  initial  capillary  leak  phase.  We  experienced 
two  cases  where  treatment  with  using  10%  pentastarch  elevated 
the  blood  pressure  and  eventually  improved  the  patients,  who 
were  both  in  the  acute  phase  of  SCLS. 
CASE REPORT
Case  1
A  37  year-old  woman  came  to  our  hospital  presenting  with 
episodes  of  resting  dyspnea,  oliguria  and  anasarca,  which  had 
started  one  day  previously.  She  had  developed  upper 
respiratory  tract  infection  3  days  before  admission,  but  she 
didn't  get  any  medication.  She  was  alert  with  a  systolic  blood 
pressure  of  40  mmHg,  heart  rate:  110  beats/min,  respiratory 
rate:  35  breaths/min  and  body  temperature:  37℃.  Auscultation 
proved  her  breath  sounds  were  normal.  The  laboratory  finding 
showed  hemoglobin:  19.2  g/dL,  hematocrit:  53%,  leukocytes: 
17,400/mm
2,  platelets:  147,000/mm
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creatinine  (BUN/Cr):  32.8/1.9  mg/dL,  total  protein/albumin:  3.7/1.7 
g/dL,  C-reactive  protein  (CRP):  3.1  mg/L  and  the  monoclonal 
IgG-kappa  was  positive.  The  laboratory  test  performed  later 
showed  C3/C4:  34.0/6.9  mg/dL  and  IgA/G/M:  101/810/102  IU/mL, 
respectively.  The  C1  esterase  inhibitor  level  was  normal  and 
bone  marrow  biopsy  showed  no  evidence  of  multiple  myeloma. 
Despite  intravenous  injection  of  a  combination  of  9  L  of  normal 
saline  solution  and  inotropic  drugs,  her  systolic  blood  pressure 
did  not  increase  and  she  developed  respiratory  failure  resulting 
from  pulmonary  edema.  The  central  venous  pressure  (CVP) 
was  3  cmH2O.  We  stopped  using  normal  saline  solution  and 
started  using  10%  pentastarch  (Pentaspan  inj,  Jeilpharm, 
Korea).  After  we  started  infusing  10%  pentastarch  500  mL  every 
8  hours,  her  blood  pressure  began  to  increase.  We  also  used 
intravenous  methylprednisolone,  aminophylline  and  calcium.  Her 
blood  pressure  and  the  CVP  recovered  to  the  normal  levels  the 
next  day.  The  hemoglobin  level  measured  at  that  time  was  16.8 
g/dL,  with  a  hematocrit  of  47%,  leukocytes:  26,200/mm
2, 
platelets:  93,000/mm
2,  BUN/Cr:  35.4/1.2  mg/dL  and  prothrombin 
time  (PT):  2.8  INR.  We  thought  that  PT  prolongation  was  a  side 
effect  of  pentastarch,  based  on  some  previous  reports. 
Therefore,  we  stopped  using  it.  The  pulmonary  edema  and 
bilateral  pleural  effusion  due  to  the  massive  injection  of  normal 
saline  solution  were  treated  with  diuretics.  There  was  no 
long-term  complication  and  no  more  attacks  during  1  year 
follow-up.
Case  2
A  36  year-old  female  came  to  the  hospital  complaining  of 
dyspnea  and  generalized  edema  that  had  started  that  very  day. 
She  developed  upper  respiratory  infection  3  days  before 
admission,  but  she  didn't  get  any  medication.  She  had  a  past 
history  of  5  admissions  at  another  hospital  for  the  same 
symptoms;  she  underwent  various  examinations  at  that  time  but 
didn't  get  the  proper  diagnosis.  She  finally  turned  out  to  have 
SCLS  at  our  hospital  2  years  before  this  admission  and  was 
being  followed  up.  She  was  alert  and  the  systolic  blood 
pressure  was  40  mmHg,  heart  rate:  130  beats/min,  respiratory 
rate:  30  breaths/min  and  a  temperature  of  36℃.  Her  breath 
sounds  were  normal.  According  to  the  laboratory  finding  taken 
on  admission,  her  hemoglobin  level  was  21.1  g/dL,  hematocrit: 
62.7%,  leukocytes:  49,700/mm
2,  platelets:  297,000/mm
2,  BUN/Cr: 
22.6/2.7  mg/dL,  total  protein/albumin:  4.4/2.5  g/dL,  CRP:  4.9 
mg/L  and  CVP:  2  cmH2O.  The  serum  protein  electrophoresis 
detected  monoclonal  gammopathy  and  the  immunofixation  test 
detected  IgG  kappa.  The  C1  esterase  inhibitor  level  was  normal 
and  the  bone  marrow  biopsy  had  no  evidence  of  multiple 
myeloma.  We  started  injecting  2  L  of  10%  pentastarch,  along 
with  inotropic  drugs,  instead  of  normal  saline  solution.  One  hour 
after  pentastarch  injection,  her  blood  pressure  began  to  rise  and 
the  CVP  was  11  cmH2O,  but  no  improvements  were  seen  in  the 
laboratory  data  that  was  checked  at  that  time.  Later,  we  injected 
methylprednisolone,  calcium,  aminophylline  and  after  that,  her 
blood  pressure  didn't  drop  and  the  patient's  condition  gradually 
got  better.  Because  she  did  not  undergo  massive  fluid  therapy, 
she  did  not  suffer  from  respiratory  failure  resulting  from 
pulmonary  edema.  During  her  5  day  hospital  stay,  the  patient 
showed  improved  an  hemoglobin  level:  10.5  g/dL,  hematocrit: 
31.0%,  BUN/Cr:  11.4/0.4  mg/dL  and  protein/albumin:  5.2/3.4 
g/dL.  The  patient  was  discharged  after  being  administered  oral 
prednisolone  and  theophylline. 
DISCUSSION
Systemic  capillary  leak  syndrome  is  a  rare  condition  that  was 
discovered  by  Clarkson  et  al  in  1960
1).  The  prodromal 
symptoms  are  fatigue,  nausea,  abdominal  pain  and  syncope.  It 
can  also  present  with  decreased  blood  pressure,  rhabdo-
myolysis,  generalized  edema  and  acute  tubular  necrosis- 
induced  renal  failure
2, 3).  This  syndrome  has  two  phases.  The 
initial  capillary  leak  phase  may  last  1  to  4  days  and  this  is  the 
essential  phase  of  acute  hypovolemia  that's  due  to  marked 
extravasation  of  intravascular  fluids  and  macromolecules. 
Therefore,  hemoconcentration,  leukocytosis,  an  increased  IgM 
concentration  and  a  decreased  concentration  of  albumin,  IgG, 
C3  and  C4  may  occur,  as  well  as  extravasation  of  up  to  70% 
of  the  plasma
3).  In  the  recruitment  phase,  the  initially 
extravasated  fluids  and  macromolecules  shift  into  blood  vessels, 
causing  a  severe  acute  intravascular  fluid  overload.  The 
disappearance  of  renal  shut-down  and  an  increased  urine 
output  are  the  main  characteristics  of  this  stage.  But  fluid 
overload  can  also  cause  pulmonary  edema,  as  in  the  case  of 
the  first  patient,  who  suffered  from  pulmonary  edema  in  the 
recruitment  phase  and  she  was  treated  by  diuretics
3). 
The  pathogenesis  of  this  syndrome  is  not  yet  clear.  Though 
some  of  these  patients  have  been  diagnosed  with  multiple 
myeloma  during  follow-up,  this  syndrome  is  supposed  to  have 
something  to  do  with  monoclonal  gammopathy  without  any 
evidence  of  multiple  myeloma
3).  According  to  Amoura  et  al. 
among  29  SCLS  patients  who  had  monoclonal  antibody,  16 
people  of  them  had  IgG  kappa,  6  of  them  had  IgG  lambda,  1 
of  them  had  IgA  lambda,  and  one  had  mixed  a  form  of  IgG 
kappa  and  IgG  lambda
4).  As  seen  from  above,  most  of  these 
patients  had  IgG  kappa,  like  our  own  patients.  Assaly  et  al 
attributed  the  mechanism  of  endothelial  cell  leak  first  to 
widening  of  the  intercellular  gaps  resulting  from  increased 
intracellular  calcium,  and  secondarily  to  endothelial  cell  damage 
and  destruction.  They  also  described  apoptosis  that  was  caused 
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damage  to  the  endothelial  cells.  They  also  emphasized  the 
importance  of  IL-2,  TNF-a,  and  leukotrien  metabolites,  according 
to  the  literature
5).  Considering  the  fact  that  not  only  our  own 
patients,  but  also  the  ones  in  various  reports  suffered  from 
upper  respiratory  infection,  there's  no  denying  that  an 
inflammatory  response  is  a  major  triggering  factor  for  this 
disease. 
Several  trials  have  been  done  with  using  theophylline, 
diuretics,  terbutaline,  steroids,  calcium  antagonist,  Ginkgo  biloba 
extracts  and  plasmapheresis  as  medication  for  SCLS,  yet  none 
of  them  have  proven  to  be  effective
6).  Considering  that  this 
disease  is  self-limiting,  conservative  treatment  in  the  acute 
phase  is  believed  to  be  very  important.  This  syndrome  can  be 
a  fatal  disease  because  cardiovascular  collapse  can  occur  in 
the  initial  capillary  leak  phase.  Approximately  one  third  of  the 
cases  died  in  the  initial  capillary  leak  phase.  Therefore,  fluid 
therapy  is  very  important  in  SCLS  since  it  reduces  the  mortality. 
Because  shifting  of  fluid  and  protein  by  capillary 
hyperpermeability  is  the  pathophysiology  of  this  syndrome, 
massive  crystalloid  fluid  therapy  would  not  be  effective  during 
the  acute  attack  and  it  exacerbates  the  pulmonary  edema. 
According  to  Fishel  et  al,  in  case  of  capillary  leak  caused  by 
infection  or  inflammation,  using  excessive  crystalloid  solution  is 
not  a  good  option  because  it  could  impede  the  oxygen  supply 
to  tissue  by  creating  pulmonary  edema,  and  too  much  normal 
saline  could  cause  metabolic  acidosis;  therefore,  using  colloid 
solution  such  as  albumin  could  be  more  efficient  in  this  type  of 
case
7).  When  used  with  an  equal  amount  with  normal  saline 
solution,  albumin  could  reduce  the  inflammatory  responses  and 
help  create  an  efficient  oxygen  supply  in  tissue.  But  albumin 
could  be  less  effective  if  it's  leaked,  so  pentastarch  is  more 
recommendable
7).  Though  we  don't  exactly  know  how  a  big 
molecule  gets  out  of  the  capillary  at  the  acute  phase  of  SCLS, 
injecting  a  higher  molecular  weight  material  than  albumin  could 
be  effective,  considering  that  hypoalbuminemia  is  present  in 
SCLS.  According  to  Atkinson  et  al,  materials  with  a  molecular 
weight  less  than  200,000  daltons  can  get  out  of  the  capillary
8). 
Considering  the  fact  that  the  mean  molecular  weight  of 
Pentastarch  is  264,000  daltons,  injecting  pentastarch  as  the 
initial  fluid  in  the  initial  capillary  leak  stage  could  be  efficient  to 
prevent  the  cardiovascular  collapse  and  pulmonary  edema 
that's  due  to  massive  fluid  therapy.  We  actually  did  see  reduced 
edema  and  elevated  blood  pressure  in  our  patients  when  they 
were  supplied  with  10%  Pentastarch.  Pentastarch  has  side 
effects  such  as  PT  prolongation.  Therefore,  Pentastarch  could 
be  very  effective  for  the  patients  in  their  acute  phase,  but  only 
if  it's  used  cautiously  enough  to  avoid  a  prolonged  PT. 
SCLS  is  a  very  rare  syndrome  with  only  60  cases  having 
been  worldwide,  and  only  1  case  has  been  reported  in  Korea
9). 
However  the  incidence  rates  are  climbing  and  we  have 
experienced  2  cases  in  the  short  term.  We  think  this  indicates 
that  SCLS  could  be  misdiagnosed  as  other  disease  such  as 
idiopathic  edema  or  polycythemia  vera,  and  so  it  is  treated  in  a 
wrong  way  that  could  lead  to  death  from  repetitive  attacks. 
In  conclusion,  having  an  awareness  of  SCLS  and  effective 
treatment  are  very  important.  Physicians  must  be  aware  of  this 
illness  and  be  well  prepared  to  treat  this  effectively  when  finding 
one  of  these  patients,  and  the  opportunity  for  conservative 
management  must  not  be  missed.  Using  10%  pentastarch 
during  the  acute  phase  of  SCLS  may  be  a  key  to  a  good 
prognosis  and  this  treatment  will  eventually  make  the  patients' 
lives  better. 
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